Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 8:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Neuromuscular Diseases in Children Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1

NCT04481048
View directory record Official record
Conditions
Neurofibromatosis 1
Interventions
N-Acetyl cysteine, Placebo
Drug · Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
8 Years to 16 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jul 24, 2026, 8:55 AM EDT
Completed Not applicable Interventional

Therapeutic Potential of Myofascial Structural Integration in Children With Cerebral Palsy

NCT01815814
View directory record Official record
Conditions
Spastic Cerebral Palsy
Interventions
Rolfing / Myofascial Structural Integration
Other
Lead sponsor
Stanford University
Other
Eligibility
1 Year to 3 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2015 · Synced Jul 24, 2026, 8:55 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age

NCT01346293
View directory record Official record
Conditions
Tetanus, Diphtheria, Pertussis, Measles, Polio
Interventions
Diphtheria and Tetanus Toxoids and Acellular Pertussis + Measles, Mumps, Rubella + Varicella Virus, Diphtheria and Tetanus Toxoids and Acellular Pertussis + Poliovirus + MMR + Varicella Virus
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
4 Years to 6 Years
Enrollment
3,372 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
71
States / cities
Birmingham, Alabama • Pinson, Alabama • Trussville, Alabama + 60 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2015 · Synced Jul 24, 2026, 8:55 AM EDT
Completed No phase listed Observational

Use of EMG to Assess Clinical Hypertonia

NCT00472914
View directory record Official record
Conditions
Cerebral Palsy, Hypertonia, Spasticity, Dystonia, Rigidity
Interventions
portable surface electromyography
Device
Lead sponsor
University of Southern California
Other
Eligibility
6 Years to 18 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Jul 24, 2026, 8:55 AM EDT
Completed Phase 2 Interventional

Absorption of Corticosteroids in Children With Juvenile Dermatomyositis

NCT00004357
View directory record Official record
Conditions
Vasculitis, Hypersensitivity, Connective Tissue Diseases, Dermatomyositis, Vasculitis
Interventions
Methylprednisolone, Prednisolone
Drug
Lead sponsor
Northwestern University
Other
Eligibility
4 Years to 21 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 21, 2011 · Synced Jul 24, 2026, 8:55 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations

NCT02124772
View directory record Official record
Conditions
Cancer
Interventions
Trametinib, Dabrafenib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Month to 17 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
10
States / cities
Phoenix, Arizona • San Francisco, California • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Jul 24, 2026, 8:55 AM EDT
Completed Phase 1Phase 2 Interventional

Oral Baclofen Pharmacokinetics and Pharmacodynamics in Children With Spasticity

NCT00607542
View directory record Official record
Conditions
Spasticity, Cerebral Palsy
Interventions
baclofen
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
2 Years to 16 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
11
States / cities
Chicago, Illinois • New Orleans, Louisiana • Baltimore, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2011 · Synced Jul 24, 2026, 8:55 AM EDT
Completed No phase listed Observational

Transient Receptor Potential Vanilloid One (TRPV1) Receptor Expression in Children With Retrosternal Pain

NCT00677378
View directory record Official record
Conditions
Epigastric Pain, Retrosternal Pain, Esophagitis, Gastrointestinal Symptoms
Interventions
Not listed
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
5 Years to 17 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 21, 2015 · Synced Jul 24, 2026, 8:55 AM EDT
Completed Not applicable Interventional

Intensive Home-based Bimanual and Lower-limb Training in Young Children With Hemiplegia

NCT02299284
View directory record Official record
Conditions
Cerebral Palsy
Interventions
Intensive Home-based Bimanual and Lower-limb Training in Young Children With Hemiplegia
Other
Lead sponsor
Teachers College, Columbia University
Other
Eligibility
2 Years to 12 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Jul 24, 2026, 8:55 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Clinical Trial of Sodium Phenylbutyrate in Children With Spinal Muscular Atrophy Types II or III

NCT00439569
View directory record Official record
Conditions
Spinal Muscular Atrophy Type II, Spinal Muscular Atrophy Type III
Interventions
sodium phenylbutyrate
Drug
Lead sponsor
Westat
Other
Eligibility
2 Years to 11 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
5
States / cities
Stanford, California • St Louis, Missouri • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2010 · Synced Jul 24, 2026, 8:55 AM EDT
Completed No phase listed Observational

Cardiac Magnetic Resonance in Children With Muscular Dystrophy

NCT01081080
View directory record Official record
Conditions
Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Limb Girdle Muscular Dystrophy
Interventions
Not listed
Lead sponsor
Cooperative International Neuromuscular Research Group
Network
Eligibility
8 Years to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 10, 2013 · Synced Jul 24, 2026, 8:55 AM EDT
Active, not recruiting No phase listed Observational

Defining Endpoints in Becker Muscular Dystrophy

NCT05257473
View directory record Official record
Conditions
Becker Muscular Dystrophy, Muscular Dystrophies, Muscular Dystrophy in Children, Muscular Dystrophy, Becker
Interventions
Not listed
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
6 Years and older · Male only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
9
States / cities
Orange, California • Aurora, Colorado • Iowa City, Iowa + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Jul 24, 2026, 8:55 AM EDT
Completed Phase 2 Interventional Results available

Open-Label, Dose-Escalating Study Assessing Safety, Tolerability, Efficacy, of RP103 in Mitochondrial Disease

NCT02023866
View directory record Official record
Conditions
Inherited Mitochondrial Disease, Including Leigh Syndrome
Interventions
Cysteamine Bitartrate
Drug
Lead sponsor
Amgen
Industry
Eligibility
6 Years to 17 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
5
States / cities
San Diego, California • Stanford, California • Akron, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2024 · Synced Jul 24, 2026, 8:55 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1

NCT00853580
View directory record Official record
Conditions
Neurofibromatosis Type 1
Interventions
Lovastatin ™, placebo
Drug · Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
8 Years to 15 Years
Enrollment
146 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2018 · Synced Jul 24, 2026, 8:55 AM EDT
Completed Phase 1 Interventional Results available

Safety, Tolerability and Pharmacokinetics of SHP465 in Children Aged 4 to 5 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT03327402
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
SHP465
Drug
Lead sponsor
Shire
Industry
Eligibility
4 Years to 5 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
8
States / cities
Little Rock, Arkansas • Orlando, Florida • Evansville, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Jul 24, 2026, 8:55 AM EDT
Enrolling by invitation Phase 2Phase 3 Interventional

Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis

NCT05374590
View directory record Official record
Conditions
Generalized Myasthenia Gravis, gMG
Interventions
Efgartigimod IV or Efgartigimod PH20 SC
Biological
Lead sponsor
argenx
Industry
Eligibility
2 Years to 18 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
3
States / cities
Chicago, Illinois • Charlotte, North Carolina • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Jul 24, 2026, 8:55 AM EDT
Completed Phase 4 Interventional Results available

Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder

NCT01238575
View directory record Official record
Conditions
Pervasive Development Disorders
Interventions
placebo, extended-release guanfacine
Other · Drug
Lead sponsor
Yale University
Other
Eligibility
5 Years to 14 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
5
States / cities
Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Jul 24, 2026, 8:55 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Efficacy and Safety of Tideglusib in Congenital Myotonic Dystrophy

NCT03692312
View directory record Official record
Conditions
Congenital Myotonic Dystrophy
Interventions
Tideglusib, Placebo
Drug
Lead sponsor
AMO Pharma Limited
Industry
Eligibility
6 Years to 16 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
9
States / cities
Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Jul 24, 2026, 8:55 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Implementation Strategy Resource Package for Behavioral Classroom Interventions: Pilot Test

NCT05489081
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder Symptoms
Interventions
Positive Behavior Management Toolkit
Behavioral
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
4 Years and older
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Jul 24, 2026, 8:55 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Microdystrophin Gene Transfer Study in Adolescents and Children With DMD

NCT03368742
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
SGT-001
Genetic
Lead sponsor
Solid Biosciences Inc.
Industry
Eligibility
4 Years to 17 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
2
States / cities
Los Angeles, California • Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Jul 24, 2026, 8:55 AM EDT
Completed Not applicable Interventional

Effects of Physical Training on Bone and Muscle Quality, Muscle Strength, and Motor Coordination in Children With NF1

NCT01058330
View directory record Official record
Conditions
Neurofibromatosis Type 1
Interventions
Plyometric training program
Other
Lead sponsor
Shriners Hospitals for Children
Other
Eligibility
4 Years to 19 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 22, 2021 · Synced Jul 24, 2026, 8:55 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of SHP465 at 6.25 mg in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-12 Years

NCT03325881
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
SHP465, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
6 Years to 12 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
41
States / cities
Dothan, Alabama • Little Rock, Arkansas • Anaheim, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2021 · Synced Jul 24, 2026, 8:55 AM EDT
Completed Phase 3 Interventional Results available

Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer

NCT00369564
View directory record Official record
Conditions
Kidney Cancer, Leukemia, Lymphoma, Neurotoxicity, Peripheral Neuropathy, Sarcoma
Interventions
glutamic acid, placebo
Drug · Other
Lead sponsor
University of South Florida
Other
Eligibility
3 Years to 20 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
6
States / cities
Fort Myers, Florida • Grand Rapids, Michigan • Minneapolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2021 · Synced Jul 24, 2026, 8:55 AM EDT
Completed Phase 3 Interventional Results available

Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Arm(s) or of Arm(s) and Leg(s) in Cerebral Palsy

NCT02002884
View directory record Official record
Conditions
Cerebral Palsy, Spasticity
Interventions
IncobotulinumtoxinA (8 Units per kg body weight), IncobotulinumtoxinA (6 Units per kg body weight), IncobotulinumtoxinA (2 Units per kg body weight)
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
2 Years to 17 Years
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
6
States / cities
Gulf Breeze, Florida • Loxahatchee Groves, Florida • Savannah, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2021 · Synced Jul 24, 2026, 8:55 AM EDT